Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.
Video content above is prompted by the following:
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.